Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma

Myriam Sasanelli, Michel Meignan, Corinne Haioun, Alina Berriolo-Riedinger, René Olivier Casasnovas, Alberto Biggi, Andrea Gallamini, Barry A. Siegel, Amanda F. Cashen, Pierre Véra, Hervé Tilly, Annibale Versari, Emmanuel Itti

Research output: Contribution to journalArticle

90 Scopus citations

Abstract

Purpose: We investigated the prognostic value of total metabolic tumour volume (TMTV) in diffuse large B-cell lymphoma (DLBCL).

Methods: TMTV was measured in 114 patients with newly diagnosed DLBCL who underwent 18F-FDG PET/CT at baseline before immunochemotherapy. TMTV was computed by summing the volumes of all lymphomatous lesions after applying the local SUVmax threshold of 41 % using semiautomatic software. Prognostic value was assessed by Kaplan-Meier estimates of progression-free survival (PFS) and overall survival (OS).

Results: Median follow-up was 39 months. Average pretherapy TMTV was 509 ± 568 cm3. The 3-year estimates of PFS were 77 % in the low metabolic burden group (TMTV ≤550 cm3) and 60 % in the high metabolic burden group (TMTV >550 cm3, p = 0.04), and prediction of OS was even better (87 % vs. 60 %, p = 0.0003). Cox regression showed independence of TMTV for OS prediction (p = 0.002) compared with other pretherapy indices of tumour burden, such as tumour bulk and the International Prognostic Index.

Conclusion: Pretherapy TMTV is an independent predictor of outcome in patients with DLBCL.

Original languageEnglish
Pages (from-to)2017-2022
Number of pages6
JournalEuropean Journal of Nuclear Medicine and Molecular Imaging
Volume41
Issue number11
DOIs
StatePublished - Jan 1 2014

Keywords

  • Diffuse large B-cell lymphoma
  • Metabolic tumour volume
  • Outcome prediction
  • PET/CT
  • Total lesion glycolysis

Fingerprint Dive into the research topics of 'Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma'. Together they form a unique fingerprint.

  • Cite this

    Sasanelli, M., Meignan, M., Haioun, C., Berriolo-Riedinger, A., Casasnovas, R. O., Biggi, A., Gallamini, A., Siegel, B. A., Cashen, A. F., Véra, P., Tilly, H., Versari, A., & Itti, E. (2014). Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma. European Journal of Nuclear Medicine and Molecular Imaging, 41(11), 2017-2022. https://doi.org/10.1007/s00259-014-2822-7